Investing.com - Corcept (NASDAQ: CORT) reported first quarter EPS of $0.14, $0.05 worse than the analyst estimate of $0.19. Revenue for the quarter came in at $105.7M versus the...
Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic,...
On Sep 16, we issued an updated research report on Corcept Therapeutics (NASDAQ:CORT) Incorporated CORT.Corcept’s only marketed drug Korlym is approved for the once-daily...
Corcept Therapeutics (NASDAQ:CORT) Incorporated CORT reported first-quarter 2020 earnings of 25 cents per share, surpassing the Zacks Consensus Estimate of 21 cents and also...
Corcept Therapeutics Inc. (NASDAQ:CORT) reported fourth-quarter 2019 earnings of 24 cents per share, in line with the Zacks Consensus Estimate. The bottom line improved from the...
Corcept Therapeutics Incorporated is a commercial-stage company, which is engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, exicorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
|Average||30.67 (+27.57% Upside)|
|No. of Analysts||6|
|Moving Averages||Strong Buy||Strong Buy||Strong Buy||Strong Buy||Strong Buy|
|Technical Indicators||Strong Buy||Strong Buy||Strong Buy||Buy||Neutral|
|Summary||Strong Buy||Strong Buy||Strong Buy||Strong Buy||Buy|